While both sodium-glucose co-transporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) or aldosterone synthase inhibitors (ASIs) have shown individual benefits in CKD, data on their combined use remain limited. This evidence concerns the gene NR3C2 and chronic kidney disease.